HomeComparePHAS vs VICI

PHAS vs VICI: Dividend Comparison 2026

PHAS yields 2853.07% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHAS wins by $281872346866.05M in total portfolio value
10 years
PHAS
PHAS
● Live price
2853.07%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$281872346867.04M
Annual income
$263,691,193,706,389,300.00
Full PHAS calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — PHAS vs VICI

📍 PHAS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHASVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHAS + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHAS pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHAS
Annual income on $10K today (after 15% tax)
$242,510.70/yr
After 10yr DRIP, annual income (after tax)
$224,137,514,650,430,900.00/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, PHAS beats the other by $224,137,514,649,901,150.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHAS + VICI for your $10,000?

PHAS: 50%VICI: 50%
100% VICI50/50100% PHAS
Portfolio after 10yr
$140936173434.01M
Annual income
$131,845,596,853,506,290.00/yr
Blended yield
93.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

PHAS
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHAS buys
0
VICI buys
0
No recent congressional trades found for PHAS or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHASVICI
Forward yield2853.07%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$281872346867.04M$988.8K
Annual income after 10y$263,691,193,706,389,300.00$623,261.32
Total dividends collected$280611873155.80M$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: PHAS vs VICI ($10,000, DRIP)

YearPHAS PortfolioPHAS Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$296,007$285,306.70$11,368$948.43+$284.6KPHAS
2$8,209,503$7,892,775.47$13,339$1,493.16+$8.20MPHAS
3$213,363,270$204,579,102.60$16,326$2,426.21+$213.35MPHAS
4$5,197,428,076$4,969,129,376.72$21,123$4,112.15+$5197.41MPHAS
5$118,688,009,645$113,126,761,603.35$29,379$7,368.23+$118687.98MPHAS
6$2,541,344,545,416$2,414,348,375,096.37$44,804$14,191.64+$2541344.50MPHAS
7$51,033,223,710,004$48,313,985,046,408.66$76,658$29,972.12+$51033223.63MPHAS
8$961,336,701,807,468$906,731,152,437,763.20$150,894$71,015.81+$961336701.66MPHAS
9$16,991,731,925,840,448$15,963,101,654,906,456.00$350,814$193,582.47+$16991731925.49MPHAS
10$281,872,346,867,038,600$263,691,193,706,389,300.00$988,809$623,261.32+$281872346866.05MPHAS

PHAS vs VICI: Complete Analysis 2026

PHASStock

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full PHAS Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this PHAS vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHAS vs SCHDPHAS vs JEPIPHAS vs OPHAS vs KOPHAS vs MAINPHAS vs NNNPHAS vs EPRTPHAS vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.